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Gene expressionIn this study, selenocystine, a nutritionally available selenoamino acid, was identiﬁed for the ﬁrst time as a
novel agent with anti proliferative activity on human keloids.
The 20 μM concentration after 48 h treatment used here was the most effective to reduce keloid ﬁbroblast
growth. We analyzed the gene expression proﬁle of selenocystine treatment response in keloid ﬁbroblasts by
the microarray system to characterize the effects of selenocystine on human keloids.
The major alterations in keloid ﬁbroblasts following selenocystine exposure included up-regulation of the
genes encoding cell death and transcription factors. Prominent down-regulation of genes involved in
development, cell adhesion and cytoskeleton, as well as extra cellular matrix genes, usually strongly up-
regulated in keloids, resulted following selenocystine exposure.
The range of the down-regulated genes and the degree of the decreased expression appeared to be correlated
with the degree of the morphological alterations in selenocystine treated keloids.felice@yahoo.it (B. De Felice).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
Keloids (OMIM 148100) are benign skin tumors occurring during
wound healing in genetically predisposed patients. Keloids are
characterized by the proliferation of dermal ﬁbroblasts, overproduction
of extracellular matrix components (ECM), an increased inﬁltration of
inﬂammatory cells including lymphocytes, mast cells (MCs) and
macrophages. Keloids spread to invade normal skin beyond the
boundaries of the original wound and do not regress spontaneously [1].
Worldwide keloid prevalence varies by geographic ancestry from
0.09% in Great Britain to 16% in the Congo [2]. Although keloid
prevalence in the United States is not well documented, they are fairly
common in youngwomen and African Americans [3]. Keloids tend to be
present, on the face (with cheek and earlobes predominating), upper
extremities, chest, presternal area, neck, back, lower extremities and
breasts.
Previously, we found that in keloid ﬁbroblasts a p53 (TP53) under
expression, due to the sequence mutations, in concert with ΔNp63 (an
isoform of the TP63 gene) activation, is central in the mechanism
involved in keloid proliferation. Suppression of apoptosis might
contribute to keloid development by means of accumulation of
continuously proliferating cells whereas the disruption or elimination
of genetically altered cells might decrease tumor potential [4–6]. The
exact etiology is still unknown and until today, there is no appropriate
treatment yet for keloid disease. It is reasonable to believe that the lackof effective therapies is due to an insufﬁcient understanding of the
disease pathology and the lack of an animal model.
Epidemiological studies, preclinical investigations and clinical
intervention trials support the role of seleno-compounds as potent
cancer chemo-preventive agents [7] especially for several major
cancers, including prostate, lung, colon and liver cancers [8,9].
Growing evidence suggested that reactive oxygen species (ROS)
played an important role in cancer cell apoptosis induced by many
anticancer agents. Interestingly, ROS production has been linked to
cytotoxicity of selenum compounds [10,11]. Selenocystine, a nutri-
tionally available seleno-amino acid, was identiﬁed as a novel agent
with broad-spectrum antitumor activity. Several human cancer cell
lines were shown to be susceptible to selenocystine, inducing a dose-
dependent apoptosis in A375, HepG2 and MCF7 cells. Mechanistic
studies showed time- and dose-dependent increases in intracellular
reactive oxygen species (ROS) in susceptible cancer cells (MCF7 and
HepG2 cells) treated with selenocystine, that was not observed in
non-susceptible normal human ﬁbroblast Hs68 cells. ROS has been
shown to play a key role in the signaling pathway of selenocystine-
induced, DNA damage-mediated apoptosis in susceptible cancer cells
[12,13].
Despite its potential applications in pharmacology and cancer
therapy, limited information is available on the action mechanism of
selenocystine.
Since we previously found a signiﬁcant correlation between ROS
generation and apoptosis data, we might hypothesize that ROS could
be an upstream mediator for p53 activation in keloid ﬁbroblasts,
leading to p53 activation that failed in keloids due to p53 mutations
together with Δp63 over-expression [4–6].
266 B. De Felice et al. / Genomics 97 (2011) 265–276In this research, we investigated, for the ﬁrst time, if selenocystine
has an anti-proliferative effect on keloid ﬁbroblasts, and we studied the
transcriptional response following exposure to selenocystine on the
gene transcription level in keloids by the use of an array gene chip.
Functional genomic approaches have become a new strategy for
biological studies, generally by use of DNA microarray systems. Such
DNA microarray technologies can be used to monitor unclear gene
interactions in a global way in human cells in response to therapeutical
treatment.
Our results demonstrated an in vitro anti-proliferative activity of
selenocystine in keloid ﬁbroblasts, decreasing keloid tumor potential.
Moreover, the DNAmicroarray system evaluated the differential gene
expression patterns of keloid ﬁbroblasts in response to treatment
with selenocystine, showing that involvement of several genes,
especially those belonging to the cytoskeleton and collagen families
are likely to be responsible for susceptibility to selenocystine effects in
keloid ﬁbroblasts. Keloids are characterized by an abnormal compo-
sition of Extra Cellular Matrix proteins, which include elevated levels
of collagen proteins [13]; these data are consistent with the fact that
keloid lesions are extremely abundant; in fact it is reported that many
genes, encoding general extracellular matrix proteins such as the
collagen family, are strongly up-regulated in keloid lesions [14].
Our results demonstrated that DNA microarray system can be
employed to evaluate the differential gene expression patterns of keloid
ﬁbroblasts in response to selenocystine exposure to a better under-
standing of the genes involved in the treatment which may potentially
lead to the development of effective therapeutic treatments.
2. Materials and methods
2.1. Cell cultures and treatment
Fresh tissues were obtained from skin lesions of 16 patients with
keloids for establishing the primary cell cultures. Fibroblasts from
keloids were isolated from samples following the same method
established by Lim et al. [15]. All experiments used cells between the
second and third passage. No morphological and biochemical diffe-
rences were found with the passage. Fibroblast cells were grown to
conﬂuence in Dulbecco's modiﬁed Eagle's medium (DMEM) containing
10% fetal bovine serum (FBS), 10 μg/mL streptomycin, and 50 IU/mL
penicillin in 5% carbon dioxide at 37 °C.
From the second passage treatment time course experiments were
set up for 24, 48, and 72 h without serum starvation, adding different
concentrations of selenocystine (10, 20, 40 μM respectively) dissolved
in 0.5 N HCl.
2.2. Phase contrast microscopy
Phase contrast images of control and treated cells were generated
with the aid of a Zeiss Axiovert 40 CFL inverted microscope equipped
with a Canon Power Shot G6 digital camera.
2.3. Cell viability analysis
To assess the cell metabolic activity, the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay was carried out
using a modiﬁed method described by Li et al. [16]. Brieﬂy, 5×104
cells were seeded in each well containing 100 μl RPMI-1640 medium
supplemented with 10% fetal bovine serum in a 96-well plate. After
incubation for 24, 48 h and 72 h respectively 50 μl MTT (Sigma-
Aldrich, St. Louis, USA) (5 mg/ml stock solution) was added and
incubated at 37 °C for another 4 h. Then 0.2 ml of DMSO was added to
stop the reactions. The absorbance of each well was determined
spectrophotometrically at 490 nm by a microplate reader (Bio-Tek,
Rockville, USA). All results shown are mean±SD of at least three
separate experiments, measuring each parameter by triplicate(n=3). Statistical signiﬁcant differences were tested by one way
analysis of variance (ANOVA), and, when the F value was signiﬁcant,
by Student–Newman–Keul's test. P value less than 0.05 (*) was
considered statistically signiﬁcant.
2.4. RNA isolation
Total RNA of ﬁbroblasts from untreated keloids and treated keloids
was extracted with NucleoSpin RNA II (Macherey-Nagel) according to
the manufacturer's instructions. A DNase I treatment was applied to
remove traces of contaminating DNA. Good-quality messenger RNA is
an essential prerequisite for the high throughput messenger RNA
proﬁling; care was taken to exclude cell cultures with degraded RNA or
poor quality. RNA quality and quantity was checked for all the samples
before proceeding to all the analysis. Quality of total RNA was checked
using Agilent 2100 Bioanalyzer platform (Agilent Technologies).
2.5. Microarray processing and data extraction
1 μg of each total RNA sample was used. To produce Cy3-labeled
cRNA, the RNA samples were ampliﬁed and labeled using the Agilent
Low RNA Input Fluorescent Linear Ampliﬁcation Kit (Agilent Tech-
nologies) following the manufacturer's protocol.
Yields of cRNA and dye-incorporation rate weremeasuredwith ND-
1000 Spectrophotometer (NanoDrop Technologies). The hybridization
procedure was performed using the Agilent Gene Expression Hybrid-
ization kit. Brieﬂy, 1.65 μg of Cy3-labeled fragmented cRNA in
hybridization buffer was hybridized overnight to Whole Human
Genome Oligo Microarrays 4x44K (Agilent Technologies).
Microarray hybridization and washing were performed using
reagents and instruments (hybridization chambers and rotating oven)
as indicated by the manufacturer (Agilent Technologies). Microarrays
were scanned usingMicroarray Scanner System (Agilent Technologies).
2.6. Microarray data analysis
The 20 CEL ﬁles generated by the Agilent Microarray Suite version
5.0 (MAS 5.0; Agilent) were converted into DCP ﬁles using dChip V1.3
software (for more information, access the followingWeb site: http://
www.dchip.org).
The Agilent Features Extraction Software (FES) was used to read
out and process the microarray image ﬁles. FES output data ﬁles were
further analyzed using the Rosetta Resolver gene expression data
analysis system (Rosetta Biosoftware).
The DCP ﬁles were normalized, and raw gene expression data were
generated using model-based analysis of the dChip system.20. For
comparison of global gene expression proﬁles between two sample sets
(e.g., control vs CJD samples), Signiﬁcance Analysis ofMicroarray (SAM)
software (for more information, access the following Web site: http://
www.stat.stanford.edu/_tibs/SAM/index.html)wasusedwith two-class
response analysis. SAM is a statistical method adapted speciﬁcally for
multiple comparison issues in the context of microarray data, and it has
been shown to be more accurate than the calculation of fold change.21
SAM identiﬁed geneswith statistically signiﬁcant changes in expression
by assimilating a set of gene-speciﬁc t tests. Each gene, i, is assigned a
score, d(i), representing the relative difference of this gene. The d(i)
score is generated based on the ratio of the change in expression of gene
i in different states (e.g, in control cases and patients) relative to the
standard deviation of repeated measurements. SAM also estimates the
percentage of genes identiﬁed by chance, based on permutations of
the measurements for each gene. In this study, genes were considered
differentially expressed if they changed more than 2-fold (see Results)
with a pb0.01. For hierarchical clustering, gene expression data
generated by dChip software were log transformed, median centered,
and analyzed for clustering according to Eisen and colleagues [17].
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mining tool of NetAffx,23which is based on theGeneOntology database
(http://www.geneontology.org). Speciﬁcation of the many gene anno-
tations was also supplemented by further online database searches.
2.7. Quantitative reverse transcription-PCR (real-time RT-PCR)
To conﬁrm the expression patterns of eight top candidate genes
(COL15A1, COL5A3, COL3A1, COL1A1, COL6A3 and FLRT3), most
down-expressed in keloid ﬁbroblasts in response to selenocystine
exposure, we performed a quantitative RT-PCR using the comparative Ct
method. Transcript levels of the target genes were normalized to β-actin
(the internal control) after correcting for differences in ampliﬁcation
efﬁciencies. RT-PCR reactions (n=3) were performed for each gene of
interest using a quantitative real-time Light-Cycler (Roche). All genes
investigated have previously been identiﬁed and sequences were
available in GenBank. Primers for qRT-PCR analysis were designed using
the Primer3 program(http://www.bioinformatic.nl/cgi-bin/primer3plus/
primer3plus.cgi).
The ﬁnal PCR reactions contained: 0.4 μM of each primer;
0.25×SYBR Green (Invitrogen); 4 mM MgCl2 and as template 5 μl of
cDNA reverse transcribed from a standardized amount of total RNA
(0.3 μg). qRT-PCR was performed using Hotstart Taq polymerase
(Qiagen) in a ﬁnal volume of 20 μl. All quantitative reactions were
subjected to: 95 °C for 15 min followed by 45 cycles at 94 °C for 15 s,
59 °C 15 s and 72 °C 15 s. Melting curve analysis was applied to all
reactions toensurehomogeneityof the reactionproduct. In addition, the
amplicon size was checked electrophoretically for each primer set and
subsequent sequencing revealed that it corresponded to the human
COL15A1, COL5A3, COL3A1, COL1A1, COL6A3 and FLRT3 transcripts
respectively, thus verifying the identity of the genes. Potential
contamination was assessed by including non-reverse transcribed
total RNA (genomic DNA contamination) and controls without
template, observing no products in these reactions.
3. Results
3.1. Treatment of keloid ﬁbroblasts with selenocystine
We determined the selenocystine concentrations at 10, 20, and
40 μM(using similar treatment times at 24, 48 and 72) that resulted in a
reduction in the number of viable cells of approximately 50% compared
to un-treated keloids using MTT test (Fig. 1). 20 μM selenocystine after
48 h was the chosen condition. Using this approach, we ensured that a
sufﬁcient number of viable cells could remain as a source of mRNA for
microarray analyses.Fig. 1.MTT cell survival assay. Cell viability of keloid ﬁbroblasts in time course experiments
cell survival obtained by analysis of three separate experiments. *pb0.05.3.2. Selenocystine impairs in vitro keloid ﬁbroblast development and
cytoskeleton
A common property that can impair both cell proliferation and
migration, with no evidence of cell death, is associated with disorga-
nization of actin cytoskeleton [18–20].
The behavior of keloid ﬁbroblasts over the 72 h period of treatment
with 20 μMselenocystinewasmonitored byphase-contrastmicroscopy
andhigh enlargement pictures analyzed. As illustrated in Fig. 2 at 48 h of
incubation time, comparing treated to untreated keloid ﬁbroblasts
morphological changes are evident that strongly suggest alterations in
the cytoskeleton organization.
We hypothesized cytostatic effects for selenocystine, rather than
cytotoxic ones, due to impairment of cell migration, differentiation and
development, and cytoskeleton damage.
3.3. Transcriptomic response to treatment with selenocystine:
microarray data analysis
Comparing the normalized signal intensities obtained for the
untreated vs treated ﬁbroblast keloid cells, in response to the treatment
with selenocystine, using a fold change cut off of 2 (pb0.01), the
expression of 8288 genes was signiﬁcantly higher, while the expression
of 8605 genes was lower (Fig. 3).
A summary of our key ﬁndings on selected differentially expressed
genes in treated keloid cells is shown in Fig. 4, Tables 1 and 2. For up-
regulated and down-regulated genes, we considered only those with at
least a 2-fold change in the level of RNA transcript expression in three
independent experiments. Differences in expressionwere calculated by
dividing the signal intensity values of genes from keloid-treated cells by
intensity values of genes from keloid-untreated cells (control).
After purging the redundant transcripts for the identical genes, we
were able to identify a group of top-ranking treated keloid ﬁbroblasts
differentially expressed genes from within the initial list of 16,000
genes (Fig. 3), which have known or suspected roles (direct or
indirect) in inﬂuencing keloid inhibiting proliferation. Only the
biological processes with groups containing genes with signiﬁcantly
changed expression were considered relevant (Fig. 4).
Selected genes from these groups can be viewed in Tables 1 and 2;
these mainly include gene products related to the cell cycle, cell
adhesion and cytoskeletal organization. Interestingly, the expression
of various genes involved in cell differentiation and development,
cytoskeleton organization, cell adhesion and extra cellular matrix was
down-regulated. Furthermore, among the up-regulated genes, many
were known to be involved in transcription and cell death.
These gene sets with signiﬁcantly altered expression are described
in more detail below.at 24, 48 and 72 h assessed by MTT assay.The histogram shows the mean values±SD of
Fig. 2. Morphological illustrations of keloid ﬁbroblasts left untreated (control) (A) or selenocystine treated for 48 h with 20 μM selenocystine (B). Bar=60 μm. The illustrations
reveal cytostatic effects for selenocystine, rather than cytotoxic ones. The 20 μM concentration used here approximately corresponds to the IC50 in vitro growth inhibitory value
obtained in the MTT colorimetric assay (see Fig. 1).
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development, cytoskeleton, cell migration, and cell adhesion
A tumor can be viewed as an aberrant organ initiated by a cancer
stem cell that undergoes processes analogous to the self-renewal and
differentiation of normal stem cells [21]. Therefore, understanding
differentiation may ultimately lead to the development of differen-
tiation therapy, which is directed toward the reversal of the
maturation arrest, thus allowing the cancer cells to differentiate and
die eventually [22].
Our array data showed down-regulation of genes involved in cell
differentiation as ITGAV, MAPK12, and a development as FZD4,
ITGB1BP2, ELAVL1, KIRREL3, CSNK2A1, and CDON.
In tumor induction and progression, the elements of the actin
cytoskeleton (or the microﬁlament system), adhesion and tissue
invasion have crucial roles in integrating and propagating signaling
circuits and dynamic morphological alterations. We found down-
regulation of genes involved in cytoskeleton as TPM3, RABGAP1,Fig. 3. Scatter plot of signal intensities of all spots bymicroarray experiments. As an example th
feature represented by a dot are shown in double logarithmic scale. X-axis: control-log signal
differential signal intensities. Blue cross: unchanged genes. Red cross: signiﬁcantly upregulate
Gray cross in legend: summary of signiﬁcantly up- and downregulated signatures.FSCN1, CAMK2N1, FILIP1L, TBCC, KIF20A, ABRA, ACTN4, and KIF6,
migration as TPM3, NUDT6, and BBS2, and cell adhesion as PCDHB6,
NDN, SNED1, CDON, CCL2, PTK7, and ITGAV.
3.5. Extra cellular matrix gene expression
Our array data showed that extra cellular matrix genes, markers of
keloid progression, were down-regulated, such as EMILIN1 and the
members of the collagen gene family, as collagen types XV, I, X, XII,
XIV, IV, V, III, and VI. The down-regulation of seven top collagen genes
and ﬁbronectin, following selenocystine exposure, was conﬁrmed by a
quantitative real time PCR assay (Fig. 5).
3.6. Increased expression of genes involved in transcription and protein
folding/modiﬁcation, and kinase/phosphatase signaling
A differential up-expression of transcription factors was charac-
terized following selenocystine treatment, such as several ZN ﬁngere data of one array experiment is shown (experiment no. 1). The signal intensities of each
intensity; y-axis: sample-log signal intensity. Red diagonal lines deﬁne the areas of 2-fold
d genes (p-valueb0.01). Green cross: signiﬁcantly downregulated genes (p-valueb 0.01).
Fig. 4. Distribution of the major functional categories of genes that were up-regulated and down-regulated by treatment of 20 μM selenocystine for 48 h in ﬁbroblast keloids. The
functions of the up-regulated and down-regulated genes were classiﬁed into 43 groups.
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MTMR3, and BRPF3, and kinase/phosphatase signaling: PRKAG2,
STK17B, PLK3, and DCLK2, usually more expressed in sensitive
tumors, in contrast to resistant tumors.
3.7. Cell death gene expression
Our array data showed that selenocystine treatment selectively
downregulated the expression of cell death related genes, as SMAD7,
BCL2L11, UNC5B, DEDD2, and GADD45G. Previous data demonstrate
that members of the Gadd45 gene family are important for anti-tumor
immune responses [23].
Gadd45 proteins cooperate in the activation of S and G2-M
checkpoints following exposure of cells to UV irradiation and other
genotoxic stresses, producing growth arrest and apoptosis [24,25].
Some of these genes differentially expressed in our list or from the same
families have been shownpreviously to be involvedwith chemotherapy
response [26–28].
4. Discussion
Global expression proﬁling in selenocystine treated keloidﬁbroblasts
allowedus tounderstand thedistinct expressionpatternsunderlying the
mechanism of action of this compound in keloid ﬁbroblasts.
Keloids are dermal tumors in which an overabundance of extracel-
lular matrix is produced during the wound healing process [29]. They
appear as raised, red and inﬂexible scar tissue that is itchy and painful.
The lesions expand over the boundaries of the initial injury site through
the rapid proliferation of ﬁbroblast-like cells [30]. Thus, keloids
represent a derailment of the protective wound-healing process.
Proliferation of ﬁbroblastic cells is one of the typical characteristics ofkeloid lesions. Keloids resist all clinical therapies and often recur, which
means that the quality of life ofmany patients is seriously compromised
by keloid disease. The lack of relevant animal models hampers efforts to
establish the etiology of keloid disease, and many attempts to explore
treatment modalities have proved unsuccessful.
Furthermore, tumorigenesis is characterized by increased motile
activity, increased rate of cell proliferation and removal of growth
inhibiting cell–cell contacts.
Tissue invasion by cancer cells requires the integration of several
actin cytoskeleton-dependent processes that include the local
modulation of contractile forces and mechano-transduction, the
turnover of cell–matrix adhesions and of the associatedmicroﬁlament
system, the locally restricted bifurcation(s) of GTPase signaling, and
the generation of specialized, transient adhesions that mediate the
focal degradation of the extracellular matrix.
Receptor activation sets up cell motility and migration, and
institution of the growth cycle. Increased expression of metallo-
proteinases allows the spread of malignant cancer cells to other sites
in the organism breaking contacts between cells and organ bounda-
ries. Several trans-membrane proteins such as growth factor
receptors, adhesion proteins and ion channels are involved, and
generate force capacity, with the sub-membranous system of actin
microﬁlaments. Perturbations in redox control of the actin-system in
cell motility and migration, actin microﬁlament formation and its
regulation are involved in cancer development [31]. Altered expres-
sion of proteins belonging to the MF-system, e.g. proﬁlin, coﬁlin,
tropomyosin, gelsolin, α-actinin, and vinculin, is frequently associated
with malignant transformation [32–38]. Integrins carry out cell–
matrix and cell–cell interactions, whereas adhesion via the cadherin
family of adhesion proteins is usually intercellular. Cadherin–cadherin
interactions link the MF-systems of adjacent cells [39–41].
Table 1
List of selected genes found to be up-regulated in keloid ﬁbroblasts following selenocystine by cDNA microarray analysis.
Gene family Gene symbol Description Accession # Log (ratio) Fold change p-value
Cellular behavior
Cell cycle PIM2 Pim-2 oncogene DB362335 0.68111 4.79854 3.11E-14
NOLC1 Nucleolar and coiled-body phosphoprotein 1 NM_004741 0.65529 4.52156 2.89E-14
MDM2 Mdm2 p53 binding protein homolog (mouse) NM_002392 0.87919 7.57169 0
MYC v-myc myelocytomatosis viral oncogene homolog (avian) AI278811 0.87438 7.48819 3.14E-16
Cell proliferation KITLG KIT ligand NM_000899 1.27079 18.65461 3.43E-21
MIA Melanoma inhibitory activity NM_006533 1.38703 24.38003 1.96E-19
AREG Amphiregulin; amphiregulin B NM_001657 0.77394 5.9421 5.35E-11
LAMP3 Lysosomal-associated membrane protein 3 NM_014398 2 100 2.25E-23
BCL6 B-cell CLL/lymphoma 6 NM_138931 0.71205 5.15291 2.54E-15
NACC2 NACC family member 2, BEN and BTB (POZ) domain containing NM_144653 0.50963 3.23316 4.16E-11
Cell death PAWR PRKC, apoptosis, WT1, regulator NM_002583 0.63436 4.30884 7.43E-14
NLRC4 NLR family, CARD domain containing 4 NM_021209 0.96621 9.25146 4.14E-06
MDM4 Mdm4 p53 binding protein homolog (mouse) NM_002393 0.55107 3.5569 4.72E-12
JAG2 Jagged 2 NM_002226 0.55192 3.56382 6.55E-06
PRKAA1 Protein kinase, AMP-activated, alpha 1 catalytic subunit NM_206907 0.69621 4.96838 5.00E-15
BCLAF1 BCL2-associated transcription factor 1; similar to Bcl-2-associated
transcription factor 1 (Btf)
NM_014739 0.48085 3.02589 2.06E-10
CD5L CD5 molecule-like NM_005894 0.78291 6.06617 0.00201
RASGRF2 Ras protein-speciﬁc guanine nucleotide-releasing factor 2 NM_006909 0.49678 3.13889 1.12E-08
EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 3 NM_004836 0.80915 6.44385 7.03E-17
GADD45B Growth arrest and DNA-damage-inducible, beta NM_015675 0.7379 5.46889 9.12E-16
BAG4 BCL2-associated athanogene 4 NM_004874 0.48388 3.04704 8.35E-10
BAG1 BCL2-associated athanogene NM_004323 0.47313 2.97252 3.19E-10
STK17B Serine/threonine kinase 17b NM_004226 0.63551 4.32031 7.09E-14
TRAF4 TNF receptor-associated factor 4 NM_004295 0.74872 5.60683 6.05E-16
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b NM_003842 0.94447 8.79975 1.29E-18
HIPK2 Homeodomain interacting protein kinase 2 NM_022740 0.56581 3.67967 2.11E-12
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) NM_004064 0.69677 4.97478 1.05E-14
PPP1R13B Protein phosphatase 1, regulatory (inhibitor) subunit 13B NM_015316 0.83714 6.87295 7.33E-16
TTBK2 Tau tubulin kinase 2 NM_173500 0.57067 3.72105 1.36E-11
MAP2K6 Mitogen-activated protein kinase kinase 6 NM_002758 0.47425 2.98026 3.48E-10
CARD14 Caspase recruitment domain family, member 14 NM_024110 0.74118 5.51036 3.01E-08
DDIT3 DNA-damage-inducible transcript 3 NM_004083 0.91568 8.23537 2.74E-18
GADD45A Growth arrest and DNA-damage-inducible, alpha NM_001924 1.10405 12.70713 4.13E-20
UBQLN1 Ubiquilin 1 NM_053067 0.82772 6.72548 3.75E-17
GSK3B Glycogen synthase kinase 3 beta NM_002093 0.54132 3.47794 0
HRK Harakiri, BCL2 interacting protein (contains only BH3 domain) NM_003806 1.9629 91.81232 5.24E-23
TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a NM_003844 0.50778 3.21947 1.33E-10
SELS Selenoprotein S NM_018445 0.5761 3.76788 1.25E-12
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 NM_002577 0.58748 3.8679 8.69E-13
TBX3 T-box 3 NM_016569 0.71401 5.17614 2.63E-15
PPP4R2 Protein phosphatase 4, regulatory subunit 2; similar to protein
phosphatase 4 regulatory subunit 2; similar to PPP4R2 protein; amyloid
beta (A4) precursor protein-binding, family B, member 1 (Fe65)
NM_174907 0.47129 2.96 3.97E-10
NOD2 Nucleotide-binding oligomerization domain containing 2 NM_022162 0.74899 5.6104 0.00453
HIPK3 Homeodomain interacting protein kinase 3 NM_005734 0.67567 4.73882 6.47E-12
BCL2L11 BCL2-like 11 (apoptosis facilitator) NM_138622 1.96051 91.30805 6.47E-23
BRAF v-raf murine sarcoma viral oncogene homolog B1 NM_004333 0.67982 4.78436 0
BAG3 BCL2-associated athanogene 3 NM_004281 0.82645 6.70577 3.91E-17
TNFRSF9 Tumor necrosis factor receptor superfamily, member 9 NM_001561 0.49761 3.14495 3.99E-06
UNC5B unc-5 homolog B (C. elegans) NM_170744 0.67046 4.68232 1.46E-14
SMAD7 SMAD family member 7 NM_005904 0.72664 5.32889 1.42E-15
BCL6 B-cell CLL/lymphoma 6 NM_138931 0.71205 5.15291 2.54E-15
PIM3 Pim-3 oncogene NM_001001852 0.61221 4.09461 2.10E-13
TNFSF9 Tumor necrosis factor (ligand) superfamily, member 9 NM_003811 0.79349 6.21572 1.39E-16
BNIP1 BCL2/adenovirus E1B 19 kDa interacting protein 1 NM_013978 0.54393 3.49888 6.62E-12
GADD45G Growth arrest and DNA-damage-inducible, gamma NM_006705 1.99732 99.38504 4.22E-23
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 NM_006290 0.94377 8.78554 2.97E-14
DEDD2 Death effector domain containing 2 NM_133328 0.857 7.19443 1.49E-17
PIM2 Pim-2 oncogene NM_006875 0.58516 3.84731 8.35E-13
TGFB2 Transforming growth factor, beta 2 NM_003238 0.93468 8.60369 6.68E-15
Cell differentiation ZNF541 Zinc ﬁnger protein 541 NM_032255 0.71296 5.16369 0.00002
SS18L1 Synovial sarcoma translocation gene on chromosome 18-like 1 NM_198935 0.67703 4.75364 1.84E-14
DPYSL5 Dihydropyrimidinase-like 5 AL713706 1.05558 11.36529 5.22E-08
RNF114 Ring ﬁnger protein 114 NM_018683 0.51953 3.30772 2.42E-11
Cell adhesion CLDN1 Claudin 1 NM_021101 1.54131 34.77872 7.28E-19
RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 NM_213589 0.70917 5.11888 2.87E-15
ZPBP2 Zona pellucida binding protein 2 NM_199321 0.72473 5.30556 0.00809
CDH7 Cadherin 7, type 2 NM_004361 0.48221 3.03534 0.00006
Cell migration ARFIP2 ADP-ribosylation factor interacting protein 2 NM_012402 0.49486 3.12511 9.39E-11
Cellular processes
Transcription GABPA GA binding protein transcription factor, alpha subunit 60 kDa NM_002040 0.57669 3.77303 1.55E-12
CBX2 Chromobox homolog 2 (Pc class homolog, Drosophila) NM_032647 0.80727 6.41607 3.05E-07
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Table 1 (continued)
Gene family Gene symbol Description Accession # Log (ratio) Fold change p-value
BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 NM_001011545 0.61863 4.15555 2.91E-09
ZNF560 Zinc ﬁnger protein 560 NM_152476 0.73975 5.49223 0.00002
ZNF585B Zinc ﬁnger protein 585B; zinc ﬁnger protein 585A NM_152279 0.47873 3.01114 2.72E-10
DLX5 Distal-less homeobox 5 NM_005221 0.79151 6.18738 0.00173
GTF3C4 General transcription factor IIIC, polypeptide 4, 90 kDa NM_012204 0.55102 3.55645 4.54E-12
KLF3 Kruppel-like factor 3 (basic) NM_016531 0.67514 4.73301 2.42E-14
ZNF254 Zinc ﬁnger protein 254 NM_004876 0.62759 4.24221 2.51E-10
EYA4 Eyes absent homolog 4 (Drosophila) NM_004100 0.85015 7.0819 2.31E-17
ZNF568 Zinc ﬁnger protein 568 NM_198539 0.65306 4.49844 3.62E-14
ZNF16 Zinc ﬁnger protein 16 NM_006958 0.79096 6.17962 1.36E-16
ZNF433 Zinc ﬁnger protein 433 BC047412 0.80003 6.31003 1.09E-16
NPAS1 Neuronal PAS domain protein 1 NM_002517 0.55773 3.61188 4.82E-12
MAFG v-maf musculoaponeurotic ﬁbrosarcoma oncogene homolog G (avian) NM_002359 0.50544 3.20215 5.22E-11
ZNF673 Zinc ﬁnger family member 673 NM_017776 0.73949 5.48892 9.37E-16
ZIK1 Zinc ﬁnger protein interacting with K protein 1 homolog (mouse) NM_001010879 0.82922 6.74873 4.25E-17
NFYA Nuclear transcription factor Y, alpha NM_002505 1.04064 10.98085 1.50E-19
NCOA7 Nuclear receptor coactivator 7 NM_181782 0.79163 6.18919 2.38E-16
RASD1 RAS, dexamethasone-induced 1 NM_016084 1.36847 23.35983 1.44E-15
ZSCAN5A Zinc ﬁnger and SCAN domain containing 5A NM_024303 0.48126 3.0287 2.10E-10
ZNF121 Zinc ﬁnger protein 121 NM_001008727 0.62392 4.20647 7.57E-11
ZNF394 Zinc ﬁnger protein 394 NM_032164 0.53231 3.40651 1.22E-11
ZNF586 Zinc ﬁnger protein 586; hypothetical LOC100288754;
hypothetical LOC100290357; hypothetical LOC100294056
NM_017652 0.577 3.77572 3.98E-12
Translation TNRC6C Trinucleotide repeat containing 6C NM_018996 0.75235 5.65387 5.76E-09
Protein degradation SPTB Spectrin, beta, erythrocytic NM_001024858 0.73976 5.49238 0.00537
TRIM36 Tripartite motif-containing 36 NM_018700 0.93509 8.61175 0.00001
PRKAG2 Protein kinase, AMP-activated, gamma 2 non-catalytic subunit AK074675 1.86727 73.66644 4.84E-22
LONRF3 LON peptidase N-terminal domain and ring ﬁnger 3 NM_024778 1.53333 34.14531 5.70E-19
KCMF1 Potassium channel modulatory factor 1 NM_020122 0.49051 3.09391 1.20E-10
LVRN Laeverin NM_173800 0.86001 7.24448 1.90E-16
ACR Acrosin; similar to Putative acrosin-like protease NM_001097 0.67623 4.74492 9.36E-08
UBQLN1 Ubiquilin 1 NM_053067 0.82772 6.72548 3.75E-17
UBE2B Ubiquitin-conjugating enzyme E2B (RAD6 homolog) BC001694 0.9421 8.75182 1.81E-18
Protein folding/
modiﬁcation
MTMR3 Myotubularin related protein 3 NM_021090 0.5066 3.21071 4.91E-11
BRPF3 Bromodomain and PHD ﬁnger containing, 3 NM_015695 0.50019 3.16366 9.22E-11
Cellular import/export SLC30A7 Solute carrier family 30 (zinc transporter), member 7 NM_133496 0.55712 3.60676 3.95E-12
OSBP Oxysterol binding protein NM_002556 0.76469 5.81683 3.53E-16
SLC34A2 Solute carrier family 34 (sodium phosphate), member 2 AF146796 0.75073 5.63293 3.25E-12
SLC39A9 Solute carrier family 39 (zinc transporter), member 9 NM_018375 0.7185 5.23001 2.12E-15
OSBPL3 Oxysterol binding protein-like 3 NM_015550 0.51349 3.26202 4.04E-11
STX1A Syntaxin 1A (brain) NM_004603 0.66097 4.58114 2.22E-14
ATP6V1C1 ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C1 NM_001695 0.5681 3.6991 1.87E-12
SCARA5 Scavenger receptor class A, member 5 (putative) NM_173833 0.73899 5.48268 2.06E-09
SCN8A Sodium channel, voltage gated, type VIII, alpha subunit NM_014191 0.77169 5.91142 2.83E-16
SLC8A2 Solute carrier family 8 (sodium/calcium exchanger), member 2;
hypothetical protein LOC100293275; hypothetical protein LOC100294378
BX110856 1.1216 13.23132 8.02E-19
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A NM_001690 0.57028 3.71772 1.69E-12
SLC30A10 Solute carrier family 30, member 10 NM_001004433 1.2349 17.17521 2.01E-12
VPS37D Vacuolar protein sorting 37 homolog D (S. cerevisiae) BC064621 0.66914 4.66815 1.67E-14
Intracellular trafﬁcking SAR1A SAR1 homolog A (S. cerevisiae) NM_020150 0.83036 6.76647 3.44E-17
Metabolism
Lipid metabolism HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 NM_181755 0.51684 3.28729 0.00304
IDI2-AS1 Chromosome 10 open reading frame 110; isopentenyl-diphosphate
delta isomerase 1
NM_018470 0.56233 3.65035 1.43E-10
AGPS Alkylglycerone phosphate synthase NM_003659 0.60756 4.05098 2.70E-13
BTN2A1 Butyrophilin, subfamily 2, member A1 NM_078476 0.64061 4.37131 5.68E-14
SAMD8 Sterile alpha motif domain containing 8 NM_144660 0.88935 7.75095 6.17E-18
ACSM3 Acyl-CoA synthetase medium-chain family member 3 NM_202000 0.54553 3.51178 0.00416
ALOX5AP Arachidonate 5-lipoxygenase-activating protein NM_001629 0.75208 5.65036 0.00441
Carbohydrate
metabolism
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 NM_004566 0.66114 4.58291 2.58E-14
ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic L34035 0.76603 5.83479 3.68E-16
KYNU Kynureninase (L-kynurenine hydrolase) NM_003937 0.52417 3.34323 4.78E-06
HKDC1 Hexokinase domain containing 1 NM_025130 2 100 2.06E-23
CHST1 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 NM_003654 0.77842 6.00378 2.62E-12
MGAT4C Mannosyl (alpha-1,3-)-glycoprotein
beta-1,4-N-acetylglucosaminyltransferase, isozyme C (putative)
NM_013244 1.5682 36.99987 2.77E-19
Nucleotide
metabolism
MCM9 Minichromosome maintenance complex component 9 NM_153255 0.67143 4.69276 1.79E-12
ZCCHC6 Zinc ﬁnger, CCHC domain containing 6 NM_024617 0.73626 5.44833 7.36E-14
RTCD1 RNA terminal phosphate cyclase domain 1 NM_003729 0.53195 3.40368 1.24E-11
Amino acid
metabolism
ODC1 Ornithine decarboxylase 1 NM_002539 0.64522 4.41799 4.50E-14
ARG2 Arginase, type II NM_001172 0.52673 3.36301 1.67E-11
UROC1 Urocanase domain containing 1 NM_144639 1.15194 14.18852 2.84E-10
Precursor and energy
metabolism
PPP1R2 Protein phosphatase 1, regulatory (inhibitor) subunit 2 NM_006241 0.58594 3.85428 7.76E-13
MOCOS Molybdenum cofactor sulfurase NM_017947 0.91588 8.23907 0
(continued on next page)
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Table 1 (continued)
Gene family Gene symbol Description Accession # Log (ratio) Fold change p-value
Metabolism
Other metabolism ATG16L1 ATG16 autophagy related 16-like 1 (S. cerevisiae) AK000897 0.77604 5.97086 2.16E-07
SULT1C2 Sulfotransferase family, cytosolic, 1C, member 2 NM_176825 0.68005 4.78689 2.14E-07
CA13 Carbonic anhydrase XIII NM_198584 0.54631 3.51808 1.35E-06
Organismal
Innate Immunity FCER1A Fc fragment of IgE, high afﬁnity I, receptor for; alpha polypeptide NM_002001 0.74214 5.52258 0.001
RSAD2 Radical S-adenosyl methionine domain containing 2 NM_080657 0.48384 3.0468 0.00005
TLR5 Toll-like receptor 5 NM_003268 0.71286 5.16254 0.00998
T-cell Immunity TREML2 Triggering receptor expressed on myeloid cells-like 2 NM_024807 0.64362 4.40166 2.50E-06
Inﬂammation CXCL2 Chemokine (C–X–C motif) ligand 2 NM_002089 1.16972 14.78161 1.78E-20
Development TUFT1 Tuftelin 1 AF086205 0.8441 6.98386 1.69E-10
ANKRD11 Ankyrin repeat domain 11 NM_013275 0.54633 3.51824 5.80E-12
GJC3 Gap junction protein, gamma 3, 30.2 kDa NM_181538 0.87284 7.46179 5.59E-09
Signaling
Kinase/phosphatase
signaling
STK17B Serine/threonine kinase 17b NM_004226 0.63551 4.32031 7.09E-14
ABL2 v-abl Abelson murine leukemia viral oncogene
homolog 2 (arg, Abelson-related gene)
NM_007314 1.19096 15.5226 9.98E-21
DUSP16 Dual speciﬁcity phosphatase 16 NM_030640 1.01157 10.26999 5.92E-19
DCLK2 Doublecortin-like kinase 2 NM_001040260 0.92071 8.3313 2.53E-18
PLK3 Polo-like kinase 3 (Drosophila); Tctex1 domain containing 4 NM_004073 0.77396 5.94237 2.37E-16
SIK1 Salt-inducible kinase 1 NM_173354 1.0806 12.03931 2.26E-19
G-protein signaling RALA v-ral simian leukemia viral oncogene homolog A (ras related) NM_005402 1.09894 12.55856 4.53E-20
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 NM_003887 0.73324 5.41049 1.20E-15
EDNRB Endothelin receptor type B NM_003991 1.39076 24.58997 2.52E-16
PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 NM_020820 0.60858 4.0605 4.58E-13
ARHGAP9 Rho GTPase activating protein 9 NM_032496 0.85954 7.23669 1.33E-14
OR10H3 Olfactory receptor, family 10, subfamily H, member 3 NM_013938 0.90295 7.99739 4.57E-13
RND2 Rho family GTPase 2 NM_005440 0.95014 8.91544 1.37E-18
Receptor signaling SPP1 Secreted phosphoprotein 1 NM_000582 2 100 0
MUC20 Mucin 20, cell surface associated NM_152673 0.54397 3.49919 6.91E-11
DTX2 Deltex homolog 2 (Drosophila) NM_020892 0.47422 2.98004 5.32E-10
SRPRB Signal recognition particle receptor, B subunit NM_021203 0.49737 3.14318 8.16E-11
CMTM8 CKLF-like MARVEL transmembrane domain containing 8 NM_178868 0.85277 7.12478 2.35E-17
Signaling mechanism
Stress
Response to
oxidative stress
TXNRD1 Thioredoxin reductase 1 NM_003330 0.56335 3.65891 2.39E-12
Response to toxins NDRG1 N-myc downstream regulated 1 NM_006096 0.47347 2.97489 3.49E-10
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 NM_021127 0.622 4.18791 0
Structural
Cytoskeleton SPIRE1 Spire homolog 1 (Drosophila) NM_020148 0.88827 7.73163 5.90E-18
MAP2 Microtubule-associated protein 2 NM_002374 1.05099 11.24583 1.27E-19
KRT33B Keratin 33B NM_002279 0.961 9.14112 3.14E-17
Extracellular matrix MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) NM_002422 0.75315 5.66436 1.02E-15
EMILIN3 Elastin microﬁbril interfacer 3; lipin 3 NM_052846 0.56878 3.70494 2.33E-12
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in comparisonwith normal ﬁbroblasts following exposure to selenocys-
tine, a seleno-amino acid, previously identiﬁed as a novel agent with
broad-spectrum antitumor activity, to explore novel treatment modali-
ties for keloids. So far, there is no clinical study on its effect on keloid
ﬁbroblasts. To elucidate the molecular mechanism of selenocystine
treatment in keloid ﬁbroblasts, the gene expression patterns in the
keloid ﬁbroblasts following selenocystine exposure was analyzed by
cDNA microarray strategy.
Carcinogenesis is a multi-step process and selenium's effect can be
on genes related to early events (i.e. initiation phase); genes related to
Phase I and Phase II enzymes involved in the metabolic activation of
selenocystine employed in this study as well as on genes that are
critical in the post-initiation phase of carcinogenesis (genes related to
cell cycle, proliferation and apoptosis). This suggests impaired cell
proliferation in treated keloid ﬁbroblasts. Reduced cell proliferation
could explain a decreased susceptibility of these blasts to treatment.
Comparison of our data with those published by other authors [14]
showed the molecular mechanisms that may explain another side of
selenocystine treatment response. It is known that keloids are
extremely abundant in extracellular matrix; in fact it is reported [14]
the up-regulation of genes encoding extracellular matrix proteins; in
addition to the previously identiﬁed collagen types I and VI.Remarkably, genes encoding general extracellular matrix proteins,
including collagen types V, XV and XVI and ﬁbronectin, have also been
found to be strongly upregulated in the keloids. While collagen type V
is a ﬁbrillar collagen that widely distributes in extracelluar matrix of
many types of tissues, a recent report indicated that expression of this
collagen is strongly up-regulated during mouse bone development
[42]. Interestingly, COL15A1 gene, encoding the alpha chain of type XV
collagen, is a member of the FACIT collagen family (ﬁbril-associated
collagens with interrupted helices), described as being expressed in
the basement membrane to underlying connective tissue stroma. Type
XV collagen has a wide tissue distribution but the strongest expression
is localized to basement membrane zones so it may function to adhere
basement membranes to underlying connective tissue stroma. In our
array experiments, it is noteworthy that, following selenocystine
treatment, the gene-expression signatures associated with extracellu-
lar matrix was signiﬁcantly down-regulated in keloid ﬁbroblasts.
Collagen types XV, I, X, XII, XIV, IV, V, III, and VI genes have been down-
regulated following selenocystine treatment such as laminin 3 and 4,
matrix metallopeptidase 13 and EMILIN1.
EMILIN1, an extracellular matrix protein with adhesive properties
[43,44], at ﬁrst described as an IFN-induced gene but however
contribute to combating cellular stress independent of the IFN system
[45], is up-regulated in responsive tumors. These results, conﬁrmed
Table 2
List of selected genes found to be down-regulated in keloid ﬁbroblasts following selenocystine exposure by cDNA microarray analysis.
Gene family Gene symbol Description Accession # Log (Ratio) Fold change p-value
Cellular behavior
Cell cycle MAPK12 Mitogen-activated protein kinase 12 NM_002969 −0.61546 −4.12531 3.05E-13
Cell proliferation EMP2 Epithelial membrane protein 2 NM_001424.4 −0.54786 −3.5307 6.58E-12
TENC1 Tensin like C1 domain containing phosphatase (tensin 2) NM_015319 −0.7033 −5.05006 3.92E-15
Cell death PDCD6IP Programmed cell death 6 interacting protein NM_013374 −1.72165 −52.6799 1.59E-22
ZMAT3 Zinc ﬁnger, matrin type 3 NM_022470 −0.59068 −3.89655 7.54E-13
CASP8 Caspase 8, apoptosis-related cysteine peptidase NM_033356 −0.66306 −4.60323 1.03E-13
TIA1 TIA1 cytotoxic granule-associated RNA binding protein CR607569 −0.93235 −8.5575 2.91E-18
Cell
differentiation
SEMA3D Sema domain, immunoglobulin domain (Ig), short basic domain,
secreted, (semaphorin) 3D
NM_152754 −0.73436 −5.42453 1.13E-15
BBS2 Bardet–Biedl syndrome 2 NM_031885 −0.59684 −3.95225 4.45E-13
RBM45 RNA binding motif protein 45 NM_152945 −0.5906 −3.89579 6.15E-13
Cell adhesion PCDHB6 Protocadherin beta 6 NM_018939 −0.92407 −8.39598 1.97E-06
SNED1 Sushi, nidogen and EGF-like domains 1; MTERF domain containing 2 AK074062 −0.82074 −6.61828 2.13E-16
CCL2 Chemokine (C-C motif) ligand 2 NM_002982 −0.93651 −8.63998 0
ITGAV Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) NM_002210 −0.61183 −4.09104 1.25E-12
Cell migration SP100 SP100 nuclear antigen L79989 −0.84323 −6.96996 7.60E-15
Angiogenesis NUDT6 Nudix (nucleoside diphosphate linked moiety X)-type motif 6;
ﬁbroblast growth factor 2 (basic)
NM_198041 −0.62591 −4.22581 2.03E-13
Cellular processes
Transcription E2F2 E2F transcription factor 2 NM_00409 −1.29359 −19.6603 3.86E-21
E2F8 E2F transcription factor 8 NM_024680 −1.4071 −25.533 3.51E-18
FRYL FRY-like AB020633 −0.61529 −4.12372 0.00048
CBX5 Chromobox homolog 5 (HP1 alpha homolog, Drosophila) AK055641 −0.89886 −7.92255 4.57E-18
ZNF217 Zinc ﬁnger protein 217 NM_006526 −0.61959 −4.16476 1.51E-13
GTF2I General transcription factor IIi NM_001518 −0.81804 −6.57718 0.00015
ZBTB7A Zinc ﬁnger and BTB domain containing 7A AL390151 −0.6267 −4.23352 1.13E-13
ZNF681 Zinc ﬁnger protein 681 CR624679 −0.76603 −5.83481 0.00077
LRPPRC Leucine-rich PPR-motif containing NM_133259 −0.75319 −5.66489 2.01E-15
ETV1 Ets variant 1 NM_004956 −1.08038 −12.0332 5.89E-19
TCF4 Transcription factor 4 BX115897 −0.58911 −3.88247 1.10E-09
TCF19 Transcription factor 19 NM_007109 −0.54824 −3.5338 3.43E-11
ZNF154 Zinc ﬁnger protein 154 AB095924 −0.58029 −3.80446 2.26E-12
ZNF658 Zinc ﬁnger protein 658; zinc ﬁnger protein 658B; zinc ﬁnger protein
658 pseudogene
NM_033160 −0.85273 −7.12402 1.69E-15
TTF2 Transcription termination factor, RNA polymerase II NM_003594 −0.87774 −7.54642 6.44E-16
ANP32A Acidic (leucine-rich) nuclear phosphoprotein 32 family, member A BC064969 −1.19678 −15.732 1.43E-20
ZNF780A Zinc ﬁnger protein 780A AK091274 −1.13071 −13.5118 3.00E-11
APITD1 Apoptosis-inducing, TAF9-like domain 1 NM_199295 −0.60464 −4.02381 3.25E-13
KIAA1549 KIAA1549 AK096022 −0.79796 −6.28004 5.96E-16
MAMLD1 Mastermind-like domain containing 1 NM_005491 −0.96936 −9.3188 7.14E-19
POU2F2 POU class 2 homeobox 2 NM_002698 −0.96091 −9.13931 1.39E-10
Translation TNRC6B Trinucleotide repeat containing 6B NM_015088 −0.60439 −4.02149 3.18E-13
EIF2S2 Eukaryotic translation initiation factor 2, subunit 2 beta, 38 kDa NM_003908 −0.63086 −4.27425 1.25E-13
Epigenetics SIRT5 Sirtuin (silent mating type information regulation 2 homolog)
5 (S. cerevisiae)
NM_031244 −0.54619 −3.51717 0.00017
HEMK1 HemK methyltransferase family member 1 NM_016173 −0.97868 −9.52089 9.75E-08
Protein
degradation
MIPEP Mitochondrial intermediate peptidase NM_005932 −0.53565 −3.43283 1.11E-11
DZIP3 DAZ interacting protein 3, zinc ﬁnger AB014575 −0.6716 −4.69465 1.24E-13
MEP1B Meprin A, beta NM_005925 −1.45285 −28.3691 1.78E-18
CPA4 Carboxypeptidase A4 NM_016352 −0.96487 −9.223 2.42E-12
FBXL16 F-box and leucine-rich repeat protein 16 NM_153350 −0.67546 −4.73654 0.00737
PGA3 Pepsinogen 3, group I (pepsinogen A); pepsinogen 4,
group I (pepsinogen A); pepsinogen 5, group I (pepsinogen A)
NM_014224 −1.05516 −11.3543 7.20E-15
USP18 Ubiquitin speciﬁc peptidase 18 NM_017414 −0.6222 −4.18985 1.54E-13
OSGEPL1 O-sialoglycoprotein endopeptidase-like 1 NM_022353 −0.838 −6.88659 8.13E-15
RECK Reversion-inducing-cysteine-rich protein with kazal motifs Z20144 −0.82583 −6.6962 0.00011
Protein folding/
modiﬁcation
PPIA Peptidylprolyl isomerase A (cyclophilin A) CR594762 −0.89288 −7.81415 6.86E-18
LRRN3 Leucine rich repeat neuronal 3 NM_018334 −0.64905 −4.45704 7.03E-14
TBCC Tubulin folding cofactor C NM_003192 −0.58235 −3.82256 9.50E-13
MOCS3 Molybdenum cofactor synthesis 3 NM_014484 −0.67127 −4.69105 1.90E-12
ST8SIA2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 NM_006011 −1.06645 −11.6533 1.19E-11
PIGZ Phosphatidylinositol glycan anchor biosynthesis, class Z NM_025163 −0.70883 −5.11487 2.93E-15
PIGN Phosphatidylinositol glycan anchor biosynthesis, class N NM_176787 −0.5461 −3.51641 3.76E-11
Cellular import/
export
SLC25A35 Solute carrier family 25, member 35 NM_201520 −0.74911 −5.61192 1.57E-12
STX11 Syntaxin 11 NM_003764 −0.67953 −4.78108 0.00645
ATP6V0E2 ATPase, H+ transporting V0 subunit e2 NM_145230 −0.73289 −5.40612 4.84E-15
LRP5 Low density lipoprotein receptor-related protein 5 NM_002335 −0.65624 −4.53149 1.28E-13
KCNA4 Potassium voltage-gated channel, shaker-related subfamily, member 4 NM_002233 −1.51635 −32.8357 2.10E-19
SLC39A4 Solute carrier family 39 (zinc transporter), member 4 AK056900 −0.8273 −6.71893 0.0001
ATP8B3 ATPase, class I, type 8B, member 3 AK125225 −0.54389 −3.49853 1.03E-11
KCNJ6 Potassium inwardly-rectifying channel, subfamily J, member 6 NM_002240 −1.92313 −83.7771 1.63E-22
GRIN2A Glutamate receptor, ionotropic, N-methyl D-aspartate 2A AK124698 −0.67218 −4.70086 0.00359
(continued on next page)
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Table 2 (continued)
Gene family Gene symbol Description Accession # Log (Ratio) Fold change p-value
Cellular process
Intracellular
trafﬁcking
KIF20A Kinesin family member 20A NM_005733 −0.55771 −3.61171 0
AP3S2 Adaptor-related protein complex 3, sigma 2 subunit BC010615 −1.0746 −11.87398 1.21E-13
SEC62 SEC62 homolog (S. cerevisiae) NM_003262 −1.38575 −24.3079 3.02E-17
KIF6 Kinesin family member 6 NM_145027 −0.65008 −4.4677 3.49E-11
Metabolism
Lipid
metabolism
PLCB3 Phospholipase C, beta 3 (phosphatidylinositol-speciﬁc) NM_000932 −0.57508 −3.75904 2.90E-12
BDH2 3-hydroxybutyrate dehydrogenase, type 2 NM_020139 −0.8031 −6.35484 2.80E-11
MECR Mitochondrial trans-2-enoyl-CoA reductase NM_016011 −0.67601 −4.7425 1.64E-14
EHHADH Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase NM_001966 −0.91507 −8.22377 3.46E-06
LDLRAP1 Low density lipoprotein receptor adaptor protein 1 NM_015627 −0.63923 −4.35747 1.59E-13
Carbohydrate
metabolism
B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 NM_006876 −0.70598 −5.08134 3.66E-15
ALDH1B1 Aldehyde dehydrogenase 1 family, member B1 NM_000692 −0.81181 −6.48349 6.78E-17
Nucleotide
metabolism
POLE2 Polymerase (DNA directed), epsilon 2 (p59 subunit) NM_002692 −0.95638 −9.04443 8.66E-18
PUS10 Pseudouridylate synthase 10 AL832208 −0.66639 −4.63861 0.00911
ELAVL1 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1
(Hu antigen R)
NM_001419 −0.71627 −5.20317 1.94E-14
NT5C1A 5′-nucleotidase, cytosolic IA NM_032526 −1.19795 −15.7744 5.28E-13
DPYSL3 Dihydropyrimidinase-like 3 NM_001387 −0.59537 −3.93884 4.77E-13
DPYSL2 Dihydropyrimidinase-like 2 NM_001386 −0.66058 −4.57702 2.26E-14
WDR36 WD repeat domain 36 NM_139281 −0.85037 −7.08557 4.93E-17
TYMS Thymidylate synthetase NM_001071 −0.57473 −3.75608 1.34E-12
SFRS12IP1 SFRS12-interacting protein 1; family with sequence similarity 159,
member B
AL832348 −0.56198 −3.64739 9.86E-11
Amino acid
metabolism
BCKDHB Branched chain keto acid dehydrogenase E1, beta polypeptide NM_183050 −1.25771 −18.1013 1.20E-19
Precursor and
energy
metabolism
ACACA Acetyl-Coenzyme A carboxylase alpha NM_198839 −0.63687 −4.33377 2.24E-11
GCK Glucokinase (hexokinase 4) NM_033508 −0.60022 −3.98309 3.01E-10
PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C NM_005398 −0.65613 −4.53033 2.76E-14
Other
metabolism
METTL7A Methyltransferase like 7A NM_014033 −1.38389 −24.2041 1.02E-21
MOBKL1A MOB1, Mps One Binder kinase activator-like 1A (yeast) NM_173468 −0.60129 −3.99289 3.75E-13
ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide;
alcohol dehydrogenase 1B (class I), beta polypeptide
NM_000667 −1.0358 −10.8593 2.49E-15
HFE Hemochromatosis NM_139005 −0.64469 −4.41256 7.33E-11
ACCS 1-Aminocyclopropane-1-carboxylate synthase homolog
(Arabidopsis)(non-functional)
NM_032592 −0.71598 −5.19978 2.85E-15
Organismal
Innate immunity KIR2DS4 Killer cell immunoglobulin-like receptor, two domains,
short cytoplasmic tail, 4; killer cell immunoglobulin-like receptor,
two domains, short cytoplasmic tail, 2; killer cell immunoglobulin-like
receptor, two domains, short cytoplasmic tail, 1; killer cell
immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3
NM_178228 −0.98314 −9.61912 1.01E-07
UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats NM_001008224 −1.24935 −17.7563 2.67E-20
BNIP3L BCL2/adenovirus E1B 19 kDa interacting protein 3-like NM_004331 −0.56923 −3.70873 1.77E-12
T-cell immunity TRAF3IP2 TRAF3 interacting protein 2 AF136407 −0.82063 −6.61658 0.00013
T-cell immunity SOCS5 Suppressor of cytokine signaling 5 NM_144949 −0.6538 −4.50611 3.08E-14
Development ITGB1BP2 Integrin beta 1 binding protein (melusin) 2 NM_012278 −0.64692 −4.43524 1.82E-06
FZD4 Frizzled homolog 4 (Drosophila) NM_012193 −0.75174 −5.64595 2.44E-12
NDN Necdin homolog (mouse) NM_002487 −0.68102 −4.79751 9.33E-15
GREM1 Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) NM_013372 −0.56276 −3.65392 2.46E-12
KIRREL3 Kin of IRRE like 3 (Drosophila) NM_032531 −0.56048 −3.63479 0.00193
Signaling
Kinase/phosphatase
signaling
MYLK Myosin light chain kinase NM_053025 −0.83352 −6.81582 3.11E-17
PTK7 PTK7 protein tyrosine kinase 7 NM_002821 −0.72149 −5.26605 1.75E-15
G-protein
signaling
GPR85 G protein-coupled receptor 85 NM_018970 −0.86177 −7.27396 0.00003
RABGAP1 RAB GTPase activating protein 1 NM_012197 −0.62391 −4.2064 1.21E-13
GNG7 Guanine nucleotide binding protein (G protein), gamma 7;
transcription elongation factor B (SIII), polypeptide 1 pseudogene
NM_052847 −1.00216 −10.0499 1.94E-10
FARP1 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1
(chondrocyte-derived)
NM_005766 −0.54582 −3.51415 5.97E-12
P2RY6 Pyrimidinergic receptor P2Y, G-protein coupled, 6 NM_176798 −1.07016 −11.7532 1.05E-09
OXTR Oxytocin receptor NM_000916 −0.7993 −6.29945 9.71E-17
ABRA Actin-binding Rho activating protein NM_139166 −1.38244 −24.1232 3.19E-17
GPR19 G protein-coupled receptor 19 NM_006143 −0.59095 −3.89895 0.00003
OPHN1 Oligophrenin 1 NM_002547 −0.57861 −3.78975 1.64E-12
C9ORF100 Chromosome 9 open reading frame 100 NM_032818 −1.27179 −18.6976 9.19E-15
Signaling, other CRIPAK Cysteine-rich PAK1 inhibitor NM_175918 −0.55391 −3.5802 4.41E-12
Receptor
signaling
PLA2R1 Phospholipase A2 receptor 1, 180 kDa NM_007366 −0.92157 −8.34771 2.09E-17
NOTCH3 Notch homolog 3 (Drosophila) AW138903 −1.00055 −10.0128 1.33E-15
NRG4 Neuregulin 4 NM_138573 −0.58188 −3.81837 1.51E-06
ATRNL1 Attractin-like 1 NM_207303 −0.97163 −9.36757 2.11E-07
LRP1 Low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) NM_002332 −0.59044 −3.89436 0
CDON Cdon homolog (mouse); hypothetical protein LOC100294410;
hypothetical protein LOC338667
NM_016952 −0.81823 −6.58003 5.72E-17
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Table 2 (continued)
Gene family Gene symbol Description Accession # Log (Ratio) Fold change p-value
Signaling mechanism
Stress
Response to
toxins
MUC1 Mucin 1, cell surface associated NM_002456 −0.85268 −7.1232 1.86E-17
FMO4 Flavin containing monooxygenase 4 NM_002022 −0.56969 −3.71274 0.00014
Structural
Cytoskeleton TPM3 Tropomyosin 3 NM_001043352 −1.24661 −17.6446 2.32E-20
FSCN1 Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) NM_003088 −0.57019 −3.71695 1.72E-12
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 BC020630 −0.73233 −5.39923 1.13E-15
FILIP1L Filamin A interacting protein 1-like NM_182909 −0.69543 −4.95936 5.43E-15
ACTN4 Actinin, alpha 4 NM_004924 −0.59977 −3.97899 3.92E-13
Extracellular
matrix
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 NM_014243 −0.64231 −4.3884 0.00029
COL15A1 Collagen, type XV, alpha 1 NM_001855 −0.80381 −6.36513 8.48E-17
LOC440104 Matrix metallopeptidase 19 AK094261 −0.9833 −9.62285 6.40E-19
COL5A3 Collagen, type V, alpha 3 NM_015719 −0.90757 −8.08302 8.34E-18
EMILIN1 Elastin microﬁbril interfacer 1; hypothetical protein NM_007046 −0.62928 −4.25875 9.39E-14
COL3A1 Collagen, type III, alpha 1 NM_000090 −1.38747 −24.40468 9.63334E-22
COL4A5 Collagen, type IV, alpha 5 NM_033380 −0.8853 −7.67886 7.68E-18
COL8A1 Collagen, type VIII, alpha 1 NM_001850 −0.54927 −3.54214 4.96E-12
COLQ Collagen-like tail subunit (single strand of homotrimer) of asymmetric
acetylcholinesterase
NM_080542 −0.64176 −4.38291 0.00345
COL10A1 Collagen, type X, alpha 1 NM_000493 −0.61256 −4.09786 2.97E-13
COL1A1 Collagen, type I, alpha 1 NM_000088.3 −1.10003 −12.5902 0
COL5A2 Collagen, type V, alpha 2 NM_000393 −0.68546 −4.84688 7.66E-15
COL12A1 Collagen, type XII, alpha 1 NM_004370 −0.72231 −5.27609 1.68E-15
COL14A1 Collagen, type XIV, alpha 1; potassium voltage-gated channel,
Shab-related subfamily, member 2
NM_021110 −0.587 −3.86364 4.12E-11
COL6A1 Collagen, type VI, alpha 1 NM_001848 −0.60975 −4.07142 2.75E-13
COL6A3 Collagen, type VI, alpha 3 NM_057166 −0.9929 −9.83774 6.16E-08
COL8A2 Collagen, type VIII, alpha 2 NM_005202 −0.53722 −3.44524 9.46E-12
MMP13 Matrix metallopeptidase 13 (collagenase 3) NM_002427 −1.12209 −13.2463 4.30E-11
FLRT3 Fibronectin NM_198391 −0.74914 −5.61224 7.12E-13
275B. De Felice et al. / Genomics 97 (2011) 265–276by quantitative real time PCR assay (Fig. 5), imply that selenocystine
treatment may be able to attenuate the expression of genes related to
the extracellular matrix generally upregulated in keloid ﬁbroblasts.Fig. 5. Relative gene expression of several collagen genes shows signiﬁcant decrease in selen
was normalized to β-actin. Each bar represents the mean value±SD. pb0.05.In conclusion, modulation of genes involved in extracellular matrix
cell proliferation and cell death provide a mechanistic basis for keloid
prevention in this cell model system.ocystine treated keloid ﬁbroblasts compared to untreated keloid ﬁbroblasts. Expression
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